ReviewJournal of virology2025
The hidden threats posed by Japanese encephalitis virus genotype V.
Review in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Superinfection Exclusion Between Japanese Encephalitis Virus Genotypes I and III Occurs During Viral Entry.Archives of virology · 2026Article
- Development of Cell Culture-Derived Hemagglutination Antigens for Japanese Encephalitis Virus Genotypes 1 and 3.Viruses · 2026Article
- Detection of Japanese encephalitis virus inParasite epidemiology and control · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Japanese encephalitis virus (JEV) remains a major cause of viral encephalitis in Asia. Among its five genotypes (GI-GV), genotype V (GV) has re-emerged and become the predominant lineage in mosquitoes in the Republic of Korea, with sporadic human cases also reported. GV JEV displays differences from other genotypes in genomic sequence, antigenicity, and pathogenicity, and animal studies indicate higher lethality. Importantly, all currently used vaccines are based on GIII strains and provide partial but insufficient protection against GV JEV, with breakthrough infections documented. These findings raise concerns that GV circulation could undermine existing control strategies. Although shifts in mosquito vectors have been observed, the broader epidemiological and clinical impact of GV JEV remains poorly defined. In the absence of specific antiviral therapies, systematic evaluation is needed to determine whether GV-based vaccines are warranted. This review summarizes current evidence on the epidemiology, molecular and biological characteristics, and vaccine protection of GV JEV, and highlights priorities for surveillance and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.